Cresco Labs, a vertically-integrated multi-state cannabis operator, agreed to acquire Cure Penn, three dispensaries in Pennsylvania, for $90m. “As we implement localization strategies tailored to state level dynamics, this transaction with Cure Penn is expected to expand our retail footprint in Pennsylvania, increase profitability, and strengthen our wholesale leadership position in the state. We’re thrilled to continue executing our playbook of achieving depth in strategic markets via rigorous capital allocation. The Cure Penn team has developed a high-performing retail platform across three dispensaries that sets up another immediately accretive acquisition for Cresco Labs," Charlie Bachtell, Cresco Labs CEO and Co-Founder.